Well Referenced

Tag: Everolimus

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

This phase I, nonrandomized, open-label study evaluated the safety and efficacy of combining the histone deacetylase inhibitor vorinostat with either the mTOR inhibitor sirolimus (V+S) or everolimus (V+E) in 40 patients with relapsed/refractory Hodgkin lymphoma who had undergone a median of five prior therapies, including brentuximab and stem cell transplantation.

Read More »
June 26, 2025 No Comments

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

This 2021 randomized pilot trial compared neoadjuvant everolimus plus letrozole (NET) with standard chemotherapy (FEC) in 40 postmenopausal women with ER-positive, HER2-negative breast cancer. The NET arm demonstrated a higher ultrasound response rate (65% vs. 40%) and better treatment completion (90% vs. 70%) compared to the FEC arm. Additionally, NET

Read More »
June 26, 2025 No Comments

Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial

This 2021 phase 2 randomized clinical trial (MIRACLE study) assessed the benefit of adding everolimus to letrozole in premenopausal women with hormone receptor-positive, ERBB2-negative advanced breast cancer who had progressed on selective estrogen receptor modulators (SERMs). A total of 199 patients were randomized to receive either everolimus (10 mg/day) with

Read More »
June 26, 2025 No Comments

TORC1 Inhibition Enhances Immune Function and Reduces Infections in the Elderly

This 2018 phase 2a randomized, placebo-controlled clinical trial evaluated the effects of selective TORC1 inhibition on immune function in 264 elderly participants. The study administered a low-dose combination of BEZ235 (a catalytic mTOR inhibitor) and RAD001 (everolimus, an allosteric mTOR inhibitor) for 6 weeks. Results showed a significant reduction in

Read More »
June 26, 2025 No Comments